Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Sell
49
AMGN Quote, Financials, Valuation and Earnings
Last price:
$344.76
Seasonality move
:
3.09%
Day range:
$341.82 - $349.23
52-week range:
$261.43 - $349.98
Dividend yield:
2.76%
P/E ratio:
26.65x
P/S ratio:
5.20x
P/B ratio:
19.30x
Volume:
2M
Avg. volume:
2.8M
1-year change:
24.06%
Market cap:
$185.6B
Revenue:
$33.2B
EPS (TTM):
$12.94
Analysts' Opinion
-
Consensus RatingAmgen, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 15 Hold ratings, and 2 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $331.59, Amgen, Inc. has an estimated downside of -3.82% from its current price of $344.75.
-
Price Target UpsideAccording to analysts, the highest upside price target is $425.00 representing 23.28% upside increase from its current price of $344.75.
Fair Value
-
According to the consensus of 27 analysts, Amgen, Inc. has -3.82% downside to fair value with a price target of $331.59 per share.
AMGN vs. S&P 500
-
Over the past 5 trading days, Amgen, Inc. has overperformed the S&P 500 by 4.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amgen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amgen, Inc. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Amgen, Inc. reported revenues of $9.6B.
Earnings Growth
-
Amgen, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Amgen, Inc. reported earnings per share of $5.93.
Enterprise value:
230.8B
EV / Invested capital:
--
Price / LTM sales:
5.20x
EV / EBIT:
22.51x
EV / Revenue:
6.43x
PEG ratio (5yr expected):
0.41x
EV / Free cash flow:
20.00x
Price / Operating cash flow:
16.18x
Enterprise value / EBITDA:
14.72x
Gross Profit (TTM):
$25.3B
Return On Assets:
7.78%
Net Income Margin (TTM):
19.52%
Return On Equity:
95.55%
Return On Invested Capital:
10.74%
Operating Margin:
26.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $26.6B | $32.3B | $35.9B | $8.5B | $9.6B | |
| Gross Profit | $19.5B | $19.5B | $25.3B | $5.1B | $6.5B | |
| Operating Income | $8.7B | $6.5B | $10.3B | $2B | $2.6B | |
| EBITDA | $12.3B | $12.1B | $15.7B | $3.4B | $3.9B | |
| Diluted EPS | $14.06 | $7.81 | $12.94 | $5.22 | $5.93 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24.4B | $24.1B | $48.5B | $26.8B | $27.9B | |
| Total Assets | $65B | $63.7B | $90.5B | $90.9B | $90.1B | |
| Current Liabilities | $14.8B | $14.3B | $17B | $20.3B | $21.8B | |
| Total Liabilities | $56.8B | $60B | $82.9B | $83.4B | $80.5B | |
| Total Equity | $8.2B | $3.7B | $7.7B | $7.5B | $9.6B | |
| Total Debt | $37.6B | $38.7B | $60.5B | $60.4B | $54.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $10.6B | $7.3B | $13.1B | $3.6B | $4.7B | |
| Cash From Investing | -$2.6B | -$27.7B | -$1.7B | -$210M | -$414M | |
| Cash From Financing | $17.2B | -$5.3B | -$11B | -$3.7B | -$2.9B | |
| Free Cash Flow | $9.4B | $6.3B | $11.5B | $3.3B | $4.2B | |
AMGN
Sector
Market Cap
$185.6B
$25.9M
Price % of 52-Week High
98.51%
51.6%
Dividend Yield
2.76%
0%
Shareholder Yield
4.52%
-1.66%
1-Year Price Total Return
24.06%
-18.99%
Beta (5-Year)
0.454
0.485
Dividend yield:
2.76%
Annualized payout:
$9.00
Payout ratio:
40.11%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$335.02
200-day SMA
Buy
Level
$299.51
Bollinger Bands (100)
Buy
Level
288.19 - 334.85
Chaikin Money Flow
Buy
Level
2.1B
20-day SMA
Buy
Level
$331.73
Relative Strength Index (RSI14)
Buy
Level
62.72
ADX Line
Buy
Level
13.17
Williams %R
Sell
Level
-16.4621
50-day SMA
Buy
Level
$332.38
MACD (12, 26)
Buy
Level
3.55
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
28.1B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.2944)
Sell
CA Score
(Annual)
Level (-1.9324)
Buy
Beneish M-Score
(Annual)
Level (-2.8796)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.4349)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Stock Forecast FAQ
In the current month, AMGN has received 10 Buy ratings 15 Hold ratings, and 2 Sell ratings. The AMGN average analyst price target in the past 3 months is $331.59.
-
Where Will Amgen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amgen, Inc. share price will drop to $331.59 per share over the next 12 months.
-
What Do Analysts Say About Amgen, Inc.?
Analysts are divided on their view about Amgen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amgen, Inc. is a Sell and believe this share price will rise from its current level to $180.00.
-
What Is Amgen, Inc.'s Price Target?
The price target for Amgen, Inc. over the next 1-year time period is forecast to be $331.59 according to 27 Wall Street analysts, 10 of them rate the stock a Buy, 2 rate the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is AMGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amgen, Inc. is a Hold. 15 of 27 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMGN?
You can purchase shares of Amgen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amgen, Inc. shares.
-
What Is The Amgen, Inc. Share Price Today?
Amgen, Inc. was last trading at $344.76 per share. This represents the most recent stock quote for Amgen, Inc.. Yesterday, Amgen, Inc. closed at $344.75 per share.
-
How To Buy Amgen, Inc. Stock Online?
In order to purchase Amgen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AMGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AMGN
Sector
P/E ratio
26.65x
23.82x
PEG ratio
0.41x
-0.01x
P/B ratio
19.30x
1.83x
Price / LTM sales
5.20x
1.56x
Growth Metrics
AMGN
Sector
Revenue growth
13.33%
4.18%
Earnings growth
13.64%
9.66%
Revenue (5-year growth)
7.4%
6.28%
Earnings forecast
$5.14
-$0.18
Profitability
AMGN
Sector
Profitability FY 2024
$21.3B
$3.1M
Return on invested capital
10.74%
-32.89%
Return on assets
7.78%
-29.56%
Return on equity
95.55%
-38.66%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
3
Estimated Next Earnings Date
Feb
3
Balance Sheet
AMGN
Sector
Total cash
$9.4B
$25.2M
Short term investments
--
$25.1M
Total assets
$91.8B
$73M
Long term debt
$54.6B
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Data Centers Be In Space?
With demand for data centers seemingly growing by the day,…
Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
56
INTC alert for Jan 24
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
64
BNR alert for Jan 24
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Sell
19
APGE alert for Jan 24
Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
